World Health Organization

Final agenda
Meeting of the Immunization Strategic Advisory Group of Experts
6-9 November 2007
Crowne Plaza Hotel, Geneva

Tuesday 6 November 2007

Time	Session	Purpose of session, target outcomes and questions for SAGE	
09:00	**Welcome - introduction**		20mn
09:20	**Report from IVB Director including status of implementation of recommendations** Presentation: J-M Okwo-Bele, WHO, 20mn Discussion 20mn	**FOR INFORMATION** - Update on key WHO activities including on implementation of recommendations from external review of IVB advisory committees - Report to SAGE on achievement of previous recommendations	40mn
10:00	**Priorities, major policy and implementation issues: reports from AMRO, EURO, and WPRO (analytical and with emphasis on challenges, specific focus on large countries and implementation/impact of SAGE recommendations)** Presentation: C. Ruiz Matus, AMRO, 20mn Discussion 20mn	**FOR INFORMATION** Provide SAGE with background information in defining global immunization priorities	2hrs
10:40	**Coffee/tea break**	**Break**	**30mn**
11:10	**Priorities, major policy and implementation issues: reports from AMRO, EURO, and WPRO (ctd)** Presentation: A. Lobanov, EURO, 20mn Discussion 20mn Presentation: Y. Baoping, WPRO, 20mn Discussion 20mn		
12:30	**Lunch**	**Break**	**1hr 30mn**

14:00	**Report from the GAVI secretariat** Presentation: J. Lob-Levyt, GAVI, 20mn Discussion 20mn	**FOR INFORMATION**	40mn
14:40	**Reports from other Advisory Committees in Immunization** GACVS report of June 2007 meeting and agenda of December 2007 meeting and report the October 2007 meeting of the Expert Committee on Biological Standardization (ECBS) GACVS reports provided ahead of meeting ECBS report D. Wood, WHO, 10mn Comments and feed-back 20mn	**FOR INFORMATION**	30mn
15:10	**Pneumococcal conjugate Target Product Profile** Introduction: Overview on AMC, TPP production process J. Hombach, WHO, 5mn Pneumococcal Global Serotype Distribution Project K. O'Brien, John Hopkins Bloomberg School of Public Health 15 mn Presentation of TPP document, D. Goldblatt, Chair of ad hoc expert advisory committee 20mn	**FOR DECISION** -Review the draft target product profile for AMC-eligible pneumococcal vaccines, as proposed by the *ad hoc* expert advisory committee. -Endorse the document with or without modifications. If considerable modifications will be deemed necessary, the final document should be endorsed by SAGE in a written process after the meeting, to allow for the TPP to be submitted to the independent assessment committee of the AMC secretariat by the end of November 2007.	2hrs 20mn
15:40	**Coffee/tea break**	**Break**	**30mn**
16:10	**Pneumococcal conjugate Target Product Profile (ctd)** Discussion 1hr 40mn		
18:00	**Cocktail**		

Wednesday 7 November 2007

08:30	**Polio eradication** Polio eradication: progress & Risks to the New Milestones, S. Cochi, Chair ACPE, 20mn Discussion 40mn Post-eradication Risk Management: deliberations & findings of the NIH consultation, K. Chumakov, US FDA, 20mn Discussion 40mn	**FOR INFORMATION AND DISCUSSION** -Update on status/prospects for eradication, including implications of the ongoing, increasingly difficult financing problems -Report from the consultation that NIH hosted in September and discussion on use of IPV for routine immunization. This discussion will feed into a later discussion by ACPE	2hrs
10:30	**Coffee/tea break**	**Break**	**30mn**

11:00	**Reports from other Advisory Committees in Immunization (Ctd)** Report of the WHO HPV Expert Advisory Group (HEAG) Presentation, P. Garcia, Chair of the 2007 HEAG meeting, 15mn Discussion 15mn Report of the April 2007 meeting of the Advisory Committee of the Initiative for Vaccine Research (IVAC) and research agenda Report will be circulated ahead of time and will not be presented Discussion 45mn	**FOR INFORMATION** **FOR INFORMATION AND DISCUSSION**	1hr 15mn
12:15	**Lunch break**	**Break**	**1hr 30mn**
13:45	**Typhoid vaccines** Review of disease burden, L. Jodar, International Vaccine Institute, Seoul, 20 mn Typhoid vaccine landscape, D. Steele, WHO, 20 mn Outcome of the international consultative meetings and suggested recommendations, D. Steele, WHO, 10 mn Discussion 1hr 10mn	**FOR DECISION** - To review the new evidence concerning the high magnitude of the burden of typhoid fever (e.g. incidence, mortality, antibiotic resistance, treatment costs) - To examine the new vaccine effectiveness data and the vaccine landscape and pipeline - To make recommendations regarding the use of typhoid fever vaccines in vulnerable populations in high risk regions - To consider to update the current vaccine position paper on typhoid vaccines	2hrs
15:45	**Coffee/tea break**	**Break**	**30mn**
16:15	**WHO Categorization of Vaccine Preventable Diseases** The WHO Vaccine Categorization Project: Overview C. Shapiro, WHO, 15 mn The WHO Vaccine Categorization Project: Methods & Results L.J. Wolfson, WHO, 15 mn Discussion 1hr	**FOR DECISION** WHO - through its normative and consultative processes, including SAGE - is undertaking an exercise to describe and categorize, according to diseases and public health priority, vaccines that are currently available but not universally recommended or vaccines that are expected to be licensed and ready for introduction in the next five years. SAGE will be asked to endorse the categorization.	1hr 30mn

Thursday 8 November 2007

08:30	**Potential Uses of WHO H5N1 Vaccine Stockpile and H5N1 vaccine** Overview, K. Fukuda, WHO, 10 mn Questions, 10mn Indonesia thoughts and concerns, T. Yoga Adimata, Director Control of Direct Transmitted Diseases, Directorate General Disease Control and Environmental Health, Ministry of Health, 10 mn Questions, 10 mn Immunogenicity of human H5N1 vaccines, M. Zambon, Enteric, Respiratory & Neurological Virus Laboratory,Health Protection Agency, 30 mn Safety of human H5N1 Vaccines, S. Salmaso, Instituto Superiore di Sanita, 30 mn Discussion on two previous presentations 30 mn Potential use of H5N1 vaccine to contain an H5N1 influenza pandemic, N. Ferguson, Imperial College, 15 mn Discussion, 15 mn Report of informal consultation on technical specifications for an international H5N1 vaccine stockpile, D. Wood, WHO, 20 mn Discussion, 15 mn General discussion: <u>How WHO Should Use Its Stockpile of H5N1 Vaccine?</u> <u>Additional questions related to H5N1 vaccine being posed to WHO</u>	**FOR INFORMATION AND DECISION** <u>FOR DECISION:</u> How WHO Should Use Its Stockpile of H5N1 Vaccine 1. Should WHO reserve part of its stockpile for pandemic containment operations? If yes, how much? 2. Should WHO reserve part of its stockpile to provide H5N1 vaccine urgently to a defined group of developing countries if an H5N1 pandemic develops? a. If yes, how should recipient countries be defined? b. If yes, how much vaccine should be allocated to each of the recipient countries? c. If yes, how much vaccine should be stored for this purpose? 3. Should WHO store the vaccine in a single stockpile or in multiple ones located regionally? <u>FOR DISCUSSION: Additional questions related to H5N1 vaccine being posed to WHO</u> 1. In the current non-pandemic period, should WHO support use of H5N1 vaccine to prevent avian H5N1 infections in countries affected by H5N1? 2. In the current non-pandemic period, should WHO support use of H5N1 vaccine to either immunologically "prime" or "pre-immunize" selected or whole populations against the possibility that an H5N1 pandemic might occur? **3.** Should WHO develop global guidance on who should receive pandemic vaccine or should this be	5hrs 30mn

		left to countries to decide for themselves?	
10:00	**Coffee/tea break**	**Break**	**30mn**
10:30	**Influenza pandemic vaccine (ctd)**		
12:30	**Lunch break**	**Break**	**1hr**
13:30	**Influenza pandemic vaccine (ctd)**		
15:30	**Coffee/tea break**	**Break**	**30mn**
16:00	**Updating of position paper on rabies** Rabies pathogenesis and evidence base for post exposure prophylaxis C. Hanlon, Kansas State Veterinary Diagnostic Laboratory, 15 mn Rational and evidence base for the safety, efficacy and cost-effectiveness of intradermal immunization, M. Warrell, University of Oxford, 15 mn Practical experience on the use of Intradermal rabies vaccination in Lanka (invited comments from O. Wilamaratne, Medical Research Institute , Colombo, no slide presentation, 5 mn) Proposed updating of the vaccine position paper, B. Bjorvatn, Narestoe, 10 mn Discussion 45 mn	**FOR DECISION**	1hr 30mn

Friday 9 November 2007

08:30	**Use of polysaccharide pneumococcal vaccine** Summary of the proposed updated position paper and draft recommendations Presentation: A. Reingold, SAGE member and Chair of SAGE working Group, 30mn Discussion 1hr	**FOR DISCUSSION** Review the evidence with respect to the following questions/issues and to propose to SAGE related recommendations on vaccine use, with a view to update the 2003 position paper. 1. Review of available data on burden of pneumococcal disease in adults and in high risk groups 2. Effectiveness of 23-valent pneumococcal	1hr 30 mn

		polysaccharide vaccine (PPV23) in elderly population 3. Effectiveness of PPV23 in high risk groups 4. Safety and efficacy of repeated doses of PPV23 in older children and adults 5. Use of PPV23 to boost kids previously immunized with the 7-valent pneumococcal conjugate vaccine (PCV7) 6. Impact of giving PPV23 to pregnant women/women of reproductive age in order to prevent pneumococcal disease in infants in the first few months of life 7. Consideration of the potential use of PPV23 to mitigate pandemic influenza disease	
10:00	**Immunization safety - Cross Departmental report** Regional perspectives: progress and challenges (5mn each) AFRO, R. Macauley AMRO, C. Ruiz Matus EMRO, E. Mohsni EURO, A. Lobanov, SEARO, H. Wibisono WPRO, Y Baoping Update on injection safety and integrated infection control strategies in health care settings S. Khamassi , WHO, 15 mn Health care waste management, Y. Chartier, WHO, 15mn Discussion 1hr	**FOR INFORMATION AND DISCUSSION**	2hrs
10:30	**Coffee/tea break**	**Break**	**30mn**
11:00	**Immunization safety - Cross Departmental report (ctd)**		
12:30	**Closing**		20mn
12:50	**End of meeting**		